Cardiovascular disease testing on the Dimension Vista® system: Biomarkers of acute coronary syndromes

Walter E. Kelley, Christina M. Lockwood, Denise R. Cervelli, Jamie Sterner, Mitchell G. Scott, Show Hong Duh, Robert H. Christenson

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Objectives: Performance characteristics of the LOCI® cTnI, CK-MB, MYO, NTproBNP and hsCRP methods on the Dimension Vista® System were evaluated. Design and methods: Imprecision (following CLSI EP05-A2 guidelines), limit of quantitation (cTnI), limit of blank, linearity on dilution, serum versus plasma matrix studies (cTnI), and method comparison studies were conducted. Results: Method imprecision of 1.8 to 9.7% (cTnI), 1.8 to 5.7% (CK-MB), 2.1 to 2.2% (MYO), 1.6 to 3.3% (NTproBNP), and 3.5 to 4.2% (hsCRP) were demonstrated. The manufacturer's claimed imprecision, detection limits and upper measurement limits were met. Limit of Quantitation was 0.040 ng/mL for the cTnI assay. Agreement of serum and plasma values for cTnI (r = 0.99) was shown. Method comparison study results were acceptable. Conclusions: The Dimension Vista® cTnI, CK-MB, MYO, NTproBNP, and hsCRP methods demonstrate acceptable performance characteristics for use as an aid in the diagnosis and risk assessment of patients presenting with suspected acute coronary syndromes.

Original languageEnglish
Pages (from-to)1444-1451
Number of pages8
JournalClinical Biochemistry
Issue number13-14
StatePublished - Sep 2009


  • Acute coronary syndrome
  • Biomarkers
  • C-reactive protein
  • Cardiac Troponin I
  • Cardiovascular diseases
  • Creatine Kinase
  • MB isoenzyme
  • Myoglobin
  • NTproBNP


Dive into the research topics of 'Cardiovascular disease testing on the Dimension Vista® system: Biomarkers of acute coronary syndromes'. Together they form a unique fingerprint.

Cite this